Sanofi and Teva's Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease
Phase 2b maintenance data for Sanofi and Teva's duvakitug demonstrated clinically meaningful and durable efficacy in ulcerative colitis and Crohn's disease.
Paris and Parsippany, NJ – February 17, 2026 – Sanofi and Teva presented findings from the RELIEVE UCCD LTE phase 2b long-term extension study for duvakitug, an investigational monoclonal antibody targeting TL1A.
The study indicated that duvakitug maintained durable clinical and endoscopic efficacy over an additional 44 weeks in patients with ulcerative colitis (UC) and Crohn's disease (CD) who had responded during the induction phase. These results reinforce earlier findings from the phase 2b induction study.
The maintenance period involved 130 patients re-randomized to receive either a 450 mg or 900 mg subcutaneous dose of duvakitug every four weeks. At the end of the study, a significant proportion of patients achieved clinical remission or endoscopic response, depending on the disease.
Duvakitug was well tolerated at both doses, with a safety profile consistent with the induction study. The results strengthen the potential of duvakitug as a therapeutic option for inflammatory bowel diseases, with ongoing phase 3 studies planned.